[ad_1]
In the United States, Canada, China, Japan, Malaysia, the United Kingdom and Germany, 5,000 patients with chronic kidney disease are currently under investigation. . The study center is located in the medical clinic and polyclinic I of the University of Würzburg. In this study, researchers are investigating whether taking an once – daily tablet of empagliflozin can prevent worsening of renal failure or death. heart disease in patients with renal insufficiency. In addition, half of the study participants will receive one tablet of empagliflozin, which they will take once a day, while the other half will receive a dummy medication without a medication called placebo.
Professor Christoph Wanner, Head of Clinical Exam: "I am delighted that we continue our longstanding collaboration with Oxford University and that we have initiated the EMPA-KIDNEY study. Since 2005, the University of Würzburg has co-ordinated and completed several major studies, such as SHARP and REVEAL, with scientists from Oxford, and together we now want to determine whether the once-a-day intake of 39; Em-pagliflozin in patients with kidney disease but without diabetes also has a positive effect.We hope to be able to save the lives of patients with kidney failure and reduce the need for dialysis treatment to the future. "
Even patients with heart disease can hope. Professor Stefan Störk, head of clinical research at the German Heart Failure Center in Würzburg (DZHI): "The EMPA-REG-OUTCOME study, in which the DZHI was also involved in Prof. Wanner's activities, has shown that empagliflozin reduces the number of deaths Decreases heart disease by 38% and hospitalizations for heart failure by 35. According to these findings, empagliflozin is now used worldwide in diabetic patients and at increased risk of heart disease or pre-existing heart disease.It must now be examined whether empagliflozin is also beneficial for non-diabetic patients and whether it can be approved for others. In parallel with the EMPA-KIDNEY study targeting patients with chronic renal failure, we launched two clinical feature studies called EMPERIAL in order to to determine if empagliflozin improves exercise capacity in heart failure patients. I am delighted that the Würzburg University Hospital and our DZHI Clinical Trial Office can make a contribution to this important and possible advance in treatment. "
Professor Christoph Maack, spokesman for the DZHI and Head of the Department of Translational Research, also welcomes the new curriculum, especially as his research focuses particularly on the interaction of the research program. heart failure and diabetes. Following an international workshop of experts organized by the European Society of Cardiology (ESC) in Brussels, which Christoph Wanner also participated in, Maack recently published a discussion paper on this topic. "More and more people in this country are suffering from heart failure and diabetes mellitus.The combination of diabetes mellitus and heart failure is also increasing steadily with the increase in obesity. It is therefore all the more important to find pharmacotherapy that has a positive effect on all diseases. "
According to Christoph Maack, the treatment of patients with diabetes and heart failure is currently a clinical dilemma. "Although many drugs reduce blood sugar, they have very different effects on the evolution of cardiovascular disease," says the cardiologist. "This suggests that it is not the drop in blood sugar, but other effects on the metabolism and / or the cardiovascular system that determine the effectiveness of various drugs. 39; empagliflozin, dapagliflozin and other drugs of this class of drugs, in addition to the protection of renal function, lowering blood pressure, weight loss and alteration of Electrolytic balance and cardiac metabolism are also discussed.Future studies will show if gliflozines also favorably affect heart failure and renal failure in non-diabetic patients. "
Information on the active substance: Empagliflozin was originally developed for the treatment of hyperglycemia in diabetic patients. It ensures that an increase in blood sugar – about 10 teaspoons a day – is excreted in the urine. This can result in a slight decrease in weight and blood pressure. And this has a positive impact on the heart and kidneys.
scientific contact:
Christoph Maack, [email protected]
Stefan Störk, [email protected]
Pr Christoph Wanner, [email protected]
Original publication:
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy600/5123545
idw 2018/10
Source link
